ClinicalTrials.gg
Enrolling by invitationNCT05276258Updated Mar 24, 2023

Cryoablation of Intercostal Nerves for Post-Operative Pain Management in Opioid-Tolerant Patients

An interventional study of cryoSPHERE Ablation and Bupivacaine in Pain and Pain, Postoperative, sponsored by The Methodist Hospital Research Institute. Enrolling by invitation at 1 site in United States. Open to participants aged 18 Years to 90 Years. Per ClinicalTrials.gov, last updated 2023-03-24.

Primary conditionPain, PostoperativeRegistry: PainReclassifiedWhy we changed it
Registry
Pain — the first condition term the registry derived for this study.
ClinicalTrials.gg
Pain, Postoperative
Why
  1. The study's listed conditions name Pain, Postoperative, a narrower term within Pain.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by The Methodist Hospital Research Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Primary completion was expected by Mar 2025, 1 year 8 months ago, but the record still lists the study as enrolling by invitation.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
75
Allocation
Non-randomized
Ages
18 Years to 90 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 1,181 studies in Pain, Postoperative with a site in United States — 204 open to participants now, 237 under way, 25 of them phase 3. Pain, Postoperative · United States.

Planned enrollment
556th of 1,099
75 · median 76
Started
2023
with 54 others
No phase
373 of 1,181
68 open now
Primary completion
2025-03
later than 18 of 236 live
Registered
894th of 1,181
by date

Among the 1,181 studies in Pain, Postoperative with a site in United States, this one is the 556th largest by planned enrollment of the 1,099 interventional ones that give a count, is one of 55 that started in 2023, is one of 373 with no phase, reaches primary completion later than 18 of the 236 other live ones, and was the 894th registered.

Pain, Postoperative

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

Browse Pain, Postoperative studies →

Open to participants now

204 of the 1,181 studies in Pain, Postoperative with a site in United States are open now. Recruiting first, the newest first:

199 more — sign in →

All 204 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 678 Pain, Postoperative studies recruiting now, 239 (35%) set no upper age limit and 329 (49%) stop at 75 or younger; 74 take children under 18; 129 take healthy volunteers.

This study: 18 Years to 90 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 1,181 studies in Pain, Postoperative with a site in United States, or all of them as a file.
02

Study summary

The main objective study is to compare the use of the cryoSPHERE probe to the standard-of-care method for pain management of patients receiving robotic-assisted thoracoscopic surgery, including reductions in opioid pain medication use and the development of post-surgical morbidity.

Read the detailed description

Patients who take more opioid medications after surgery tend to have longer hospital stays, and they are at risk of developing pneumonia and other postoperative morbidities. Opioid-tolerant patients are at a higher risk of developing these morbidities because they often require higher doses of opioid medications to manage their post-operative pain. Reducing post-operative pain in these patients through non-opioid means helps reduce their risk of developing morbidities, and is potentially a more effective form of pain management, particularly in this patient population.

This is a single-center, prospective cohort registry with a historical control, and an estimated duration of 2 years. This study's primary objective is to evaluate the cryoSPHERE probe for ablation in pain control after surgery (measured using opioid medication). The secondary objectives are the evaluation of morbidities, length of stay, cost, and incidence of neuroma formation.

We plan to recruit 75 patients who will receive the cryoSPHERE probe and compare them to 75 patients who did not receive the cryoSPHERE probe. The experimental group will receive cryoSPHERE ablation of intercostal nerves and liposomal bupivacaine. The historical control group will have had robotic-assisted thoracoscopic surgery and an intercostal nerve block with liposomal bupivacaine and no cyroSPHERE probe.

03

Conditions studied

  • Pain
  • Pain, Postoperative

Browse trials for

Keywords

  • pain management
  • pulmonary surgical procedures
  • robotic surgical procedures
  • pneumonectomy
  • nerve block
  • neuroma
  • analgesics, opioid
  • bupivacaine
  • length of stay
  • drug tolerance
04

In context

Pain, Postoperative Reclassified

5,680 studies on the registry are indexed under Pain, Postoperative; 1,243 are open to participants now.

This study's planned enrollment of 75 is close to the median of 75 across 4,859 interventional studies indexed under Pain, Postoperative.

Browse Pain, Postoperative studies →

Lead sponsor

The Methodist Hospital Research Institute is the lead sponsor of 162 studies on the registry; 61 are open to participants now.

Of its 28 completed or terminated interventional studies of FDA-regulated products, 18 (64%) have results posted.

Compared within Pain, Postoperative, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Pain. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 90 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male and female patients 18-90 years of age
  • Diagnosis requiring robotic-assisted thoracoscopic surgery
  • Daily opioid use for at least 30 days consecutively at any point during the last 12 months prior to surgery or using opioids at the time of study enrollment
  • Experimental group only: agreement and consent to comply with all aspects of the study protocol and data collection, including follow-up contact.

Exclusion criteria

Exclusion Criteria:

  • Previous major surgery at the operative site (thoracotomy)
  • Allergy to aluminum
  • Allergy to plastics
  • Allergy to bupivacaine
  • Shingles disease
  • Demyelinating illnesses
  • Involvement with other interventional studies
06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
75 participants (estimated)

Study arms

  • Experimental
    Nerve Block Using Liposomal Bupivacaine and cryoSPHERE Ablation

    The experimental group (75 participants) will undergo intercostal nerve block using liposomal bupivacaine and the cryoSPHERE ablation of intercostal nerves during robotic-assisted thoracoscopic operation at Houston Methodist Hospital.

    Device: cryoSPHERE Ablation · Drug: Bupivacaine

  • Other
    Historical Controls

    A total of 75 propensity score-matched historical controls will be selected from the pool of patients who had standard intercostal nerve block using liposomal bupivacaine alone at Houston Methodist Hospital from January 1, 2017 through January 1, 2022, inclusively.

    Drug: Bupivacaine

Interventions

  • DevicecryoSPHERE Ablation

    The cryoSPHERE probe will be introduced through a thoracoscopic port and placed inferior to each rib level and 2cm lateral and away from the sympathetic chain when clearly visible or 4cm lateral and away from the spine when the sympathetic chain is not visible. Levels to be ablated are intercostal spaces 3-9. Each intercostal nerve will undergo cryogenic ablation of -70 degrees Celsius for 120 seconds. The probe will be firmly pushed against the nerve for 120 seconds and will only be released from the nerve when the probe has thawed. Axons within the intercostal nerve that send pain signals will be destroyed distal to the cryoablation site. However, the tubules structures (epineurium, perineurium, and endoneurium) of the nerve will remain intact, allowing the axons to regenerate and nerve function to resume after one to three months.

    Also known as: cryoSPHERE

  • A long needle will be introduced through a thoracoscopic port, and in each intercostal space (1-11), 1ml of liposomal bupivacaine will be injected onto the intercostal nerves to induce intercostal nerve blockage.

    Also known as: liposomal bupivacaine, Exparel

07

What researchers measure

Primary outcomes

  1. Opioid Use Within 24 Hours After Chest Tube Removal

    Opioid use measured as the daily dose of milligram morphine equivalents (MME)

    Time frame: From the time of chest tube removal to 24 hours after chest tube removal

Secondary outcomes

  1. Total Emergent Adverse Effects (TEAE)

    Morbidity, defined as total emergent adverse effects (TEAE) for the experimental group vs. control

    Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery

  2. Length of Hospital Stay

    Time spent in the hospital from admission for surgery until discharge or death

    Time frame: From admission to discharge or death, up to 1 year after surgery

  3. Mean Cost of Hospital Care

    Total cost of billed medical care for the surgery

    Time frame: From admission to discharge or death, up to 1 year after surgery

  4. Number of Readmissions

    The number of readmissions to the hospital

    Time frame: From initial admission for surgery to 28 days after surgery

  5. Neuroma Formation

    The formation of a neuroma around the site of nerve block administration

    Time frame: Time of discharge (up to 1 year after surgery), 3 months after surgery, and 6 months after surgery

  6. Pain Score

    Patient's perceived pain level on a scale of 1 to 10

    Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery

  7. PROMIS3a Pain Intensity

    Patient's perceived pain level on a scale of 3-15, per PROMIS Pain Intensity Short Form 3a v1.0

    Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery

  8. PROMIS8a Pain Interference

    Patient's perceived pain interference level on a scale of 8-40, per PROMIS Pain Interference Adult Form

    Time frame: Time of discharge (up to 1 year after surgery), 5 weeks after surgery, 3 months after surgery, and 6 months after surgery

  9. Opioid Use after Surgery

    Mean daily opioid use after surgery measured in milligram morphine equivalents (MME)

    Time frame: Day 1 after surgery, day 3 after surgery, 5 weeks after surgery, 3 months after surgery

08

Study locations

1 site
09

References and documents

Publications

  • Goto T. What is the best pain control after thoracic surgery? J Thorac Dis. 2018 Mar;10(3):1335-1338. doi: 10.21037/jtd.2018.03.63. No abstract available. PubMed 29708130 ↗
  • Rice DC, Cata JP, Mena GE, Rodriguez-Restrepo A, Correa AM, Mehran RJ. Posterior Intercostal Nerve Block With Liposomal Bupivacaine: An Alternative to Thoracic Epidural Analgesia. Ann Thorac Surg. 2015 Jun;99(6):1953-60. doi: 10.1016/j.athoracsur.2015.02.074. Epub 2015 Apr 23. PubMed 25912739 ↗
  • Nobel TB, Adusumilli PS, Molena D. Opioid use and abuse following video-assisted thoracic surgery (VATS) or thoracotomy lung cancer surgery. Transl Lung Cancer Res. 2019 Dec;8(Suppl 4):S373-S377. doi: 10.21037/tlcr.2019.05.14. No abstract available. PubMed 32038918 ↗
  • Brown LM, Kratz A, Verba S, Tancredi D, Clauw DJ, Palmieri T, Williams D. Pain and Opioid Use After Thoracic Surgery: Where We Are and Where We Need To Go. Ann Thorac Surg. 2020 Jun;109(6):1638-1645. doi: 10.1016/j.athoracsur.2020.01.056. Epub 2020 Mar 3. PubMed 32142814 ↗
  • Kim MP, Chan EY, Meisenbach LM, Dumitru R, Brown JK, Masud FN. Enhanced recovery after thoracic surgery reduces discharge on highly dependent narcotics. J Thorac Dis. 2018 Feb;10(2):984-990. doi: 10.21037/jtd.2018.01.99. PubMed 29607171 ↗
  • AtriCure, I., croSPHERE Probe Package Insert.
  • Graves CE, Moyer J, Zobel MJ, Mora R, Smith D, O'Day M, Padilla BE. Intraoperative intercostal nerve cryoablation During the Nuss procedure reduces length of stay and opioid requirement: A randomized clinical trial. J Pediatr Surg. 2019 Nov;54(11):2250-2256. doi: 10.1016/j.jpedsurg.2019.02.057. Epub 2019 Mar 17. PubMed 30935731 ↗

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2023 (actual). Primary completion is estimated for Mar 2025, 25 months after the start.

Of 2,113 non-industry interventional studies with no phase under Pain, Postoperative, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 6 and three quarters within 23. This study's planned 25 months is above that.

Counting every sponsor, half of 2,126 studies reached it within 11 months; a quarter within 6 and three quarters within 23.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 14, 2022
First posted
Mar 11, 2022
StartActual
Feb 1, 2023
Primary completionEst.
Mar 15, 2025
CompletionEst.
Sep 15, 2025
Last update
Mar 24, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 24, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT05276258
Responsible party
Min P. Kim, MD (Distinguished Professor of Surgery, The Methodist Hospital Research Institute) — Principal investigator
First posted
Mar 11, 2022
Start date
Feb 1, 2023
Primary completion
Mar 15, 2025 (estimated)
Completion
Sep 15, 2025 (estimated)
Last update
Mar 24, 2023

Study contacts

Min Kim, MD
principal investigator · The Methodist Hospital Research Institute

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion